These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16490868)

  • 1. Established and emerging uses of cytoprotection in head and neck cancer.
    Rosenthal DI
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):129-30. PubMed ID: 16490868
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
    Huang R; Yu H; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoprotection for radiation-associated normal tissue injury.
    Mao J; Fatunase OA; Marks LB
    Cancer Treat Res; 2008; 139():307-27. PubMed ID: 18236722
    [No Abstract]   [Full Text] [Related]  

  • 8. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 10. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
    Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
    Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence.
    Xunclà M; Barquinero JF; Caballín MR; Craven-Bartle J; Ribas M; de Vega JM; Barrios L
    Int J Radiat Biol; 2008 Mar; 84(3):243-51. PubMed ID: 18300025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiobiologic modeling of cytoprotection effects in radiotherapy.
    Plataniotis GA; Dale RG
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):236-42. PubMed ID: 17448877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):1-83. PubMed ID: 12577235
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
    Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
    Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
    Batcha M
    Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiotherapy-induced salivary dysfunction.
    Ship JA; Hu K
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):29-36. PubMed ID: 15726520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):1-2. PubMed ID: 10348254
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
    de Castro G; Federico MH
    Curr Opin Oncol; 2006 May; 18(3):266-70. PubMed ID: 16552239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.